{
  "report-package": "inph-2021-12-31AR.zip",
  "date": "2021-12-31",
  "lei": "9695002Y8420ZB8HJE29",
  "system": "ESEF",
  "country": "FR",
  "langs": [
    "fr"
  ],
  "report": "inph-2021-12-31AR/reports/inph-2021-12-31AR.xhtml",
  "viewer": "inph-2021-12-31AR/reports/ixbrlviewer.html",
  "xbrl-json": "inph-2021-12-31AR.json",
  "sha256sum": "7b5f1785e8315e6e96e845a6de56960d1fb28a2d829c080c3139130c1f2b841e",
  "errors": [
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:Assets in link role http://www.innate-pharma.com/role/tatdelasituationfinancirecourantnoncourant reported sum 267,496,000 computed sum 267,497,000 context i9be2f4f477104d918a6bbfb7bb960b19_I20211231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:EquityAndLiabilities in link role http://www.innate-pharma.com/role/tatdelasituationfinancirecourantnoncourant reported sum 267,496,000 computed sum 267,495,000 context i9be2f4f477104d918a6bbfb7bb960b19_I20211231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:NoncurrentLiabilities in link role http://www.innate-pharma.com/role/tatdelasituationfinancirecourantnoncourant reported sum 105,959,000 computed sum 105,958,000 context i7ae2ada0760d4b93af2020bcc87af448_I20201231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:Equity in link role http://www.innate-pharma.com/role/tatdelasituationfinancirecourantnoncourant reported sum 107,440,000 computed sum 107,441,000 context i9be2f4f477104d918a6bbfb7bb960b19_I20211231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:IncreaseDecreaseInWorkingCapital in link role http://www.innate-pharma.com/role/tatdesfluxdetrsoreriemthodeindirecte reported sum 9,884,000 computed sum 9,883,000 context i4d6f23990f694c0a864e7b94d5368925_D20210101-20211231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:IncreaseDecreaseInWorkingCapital in link role http://www.innate-pharma.com/role/tatdesfluxdetrsoreriemthodeindirecte reported sum 49,206,000 computed sum 49,204,000 context if5faa2b5799642f78d69292922636aac_D20200101-20201231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:IncreaseDecreaseInCashAndCashEquivalents in link role http://www.innate-pharma.com/role/tatdesfluxdetrsoreriemthodeindirecte reported sum -33,037,000 computed sum -33,039,000 context i4d6f23990f694c0a864e7b94d5368925_D20210101-20211231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:IncreaseDecreaseInCashAndCashEquivalents in link role http://www.innate-pharma.com/role/tatdesfluxdetrsoreriemthodeindirecte reported sum -66,096,000 computed sum -66,095,000 context if5faa2b5799642f78d69292922636aac_D20200101-20201231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:CashFlowsFromUsedInFinancingActivities in link role http://www.innate-pharma.com/role/tatdesfluxdetrsoreriemthodeindirecte reported sum -1,177,000 computed sum -1,178,000 context if5faa2b5799642f78d69292922636aac_D20200101-20201231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    },
    {
      "sev": "INCONSISTENCY",
      "code": "xbrl.5.2.5.2:calcInconsistency",
      "msg": "Calculation inconsistent from ifrs-full:CashFlowsFromUsedInOperatingActivities in link role http://www.innate-pharma.com/role/tatdesfluxdetrsoreriemthodeindirecte reported sum -51,767,000 computed sum -51,768,000 context if5faa2b5799642f78d69292922636aac_D20200101-20201231 unit i02452afab21c42349f2d36d709a9b431_e88d9918-4a9b-3a03-83ff-99baed260fc9 unreportedContributingItems none"
    }
  ],
  "added": "2022-04-05"
}